COVID-19 vaccine efficacy data: solid enough to delay second dose?
- PMID: 34119060
- PMCID: PMC8192085
- DOI: 10.1016/S0140-6736(21)01046-1
COVID-19 vaccine efficacy data: solid enough to delay second dose?
Conflict of interest statement
JFRR holds shares and was a Director and Chief Scientific Officer, 2003–13, at Oncimmune, which was spun out from the University of Nottingham, UK, as a company for early diagnosis of cancer using detection of autoantibodies to cancer antigens. In 2020, Oncimmune used the technology platform for measuring antibodies to SARS-COV-2 antigens; JFRR had not been involved in this development. HFS declares no competing interests.
Comment in
-
COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.Lancet. 2021 Jun 12;397(10291):2249-2250. doi: 10.1016/S0140-6736(21)01059-X. Lancet. 2021. PMID: 34119061 Free PMC article. No abstract available.
Comment on
-
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18. Lancet. 2021. PMID: 33610193 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical